---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-106149"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2023-10-03T23:59:59+00:00"
generated_at: "2026-06-10T05:38:14.941565+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics updates investor deck highlighting pipeline, Allo-Evasion 3.0, and cash runway into 2026

## Summary
- Cash, cash equivalents and investments of $301M at Q2 2023; runway extends into 2026.
- ELiPSE-1 trial for CNTY-101 (iNK CD19) ongoing; initial data expected by end of 2023, PoC in 2024.
- Pipeline includes CNTY-102 (iT CD19/CD22 dual-target) and CNTY-107 (iT Nectin-4); BMS collaboration for CNTY-104 (AML) and CNTY-106 (myeloma).
- Allo-Evasion 3.0 incorporates 4 edits (β2M KO, CIITA KO, HLA-E KI, HLA-G KI) to protect against NK cell killing.
- CNTY-101 designed with Allo-Evasion to enable repeat dosing without additional lymphodepletion; first CD19 agent with this approach.

## SEC filing metadata
- accession: 0001104659-23-106149
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2023-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465923106149/0001104659-23-106149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465923106149/tm2327303d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-106149
- JSON: https://secwatch.observer/filing/0001104659-23-106149.json
- Plain text: https://secwatch.observer/filing/0001104659-23-106149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.